A functional variant in *TIRAP*, also known as *MAL*, and protection against invasive pneumococcal disease, bacteraemia, malaria and tuberculosis

Chiea C. Khor[1,‡,§], **Stephen J. Chapman**[1,2,‡], **Fredrik O Vannberg**[1], **Aisling Dunne**[3], **Caroline Murphy**[3], **Edmund Y Ling**[1], **Angela J. Frodsham**[1], **Andrew J Walley**[1,*], **Otto Kyrieleis**[3], **Amir Khan**[3], **Christophe Aucan**[1], **Shelley Segal**[4], **Catrin E. Moore**[4], **Kyle Knox**[5], **Sarah J. Campbell**[1], **Christian Lienhardt**[6], **Anthony Scott**[7], **Peter Aaby**[8], **Oumou Y. Sow**[9], **Robert T. Grignani**[1,§], **Jackson Sillah**[10], **Girogio Sirugo**[10], **Nobert Peshu**[7], **Thomas N. Williams**[7], **Kathryn Maitland**[7], **Robert J. O. Davies**[2], **Dominic P. Kwiatkowski**[1,4,10], **Nicholas P. Day**[11], **Djamel Yala**[12], **Derrick W. Crook**[4], **Kevin Marsh**[7], **James A Berkley**[7], **Luke A.J. O'Neill**[3,¶], and **Adrian V. S. Hill**[1,¶]

[1]The Wellcome Trust Centre for Human Genetics, University of Oxford, UK [2]Osler Chest Unit, Churchill Hospital, Oxford, UK [3]School of Biochemistry and Immunology, Trinity College, Dublin, Ireland [4]Department of Paediatrics, John Radcliffe Hospital, Oxford, UK [5]Department of Microbiology, John Radcliffe Hospital, Oxford, UK [6]Institut de Recherche pour le Developpement, Dakar, Senegal [7]Kenya Medical Research Institute/Wellcome Trust Programme, Centre for Geographic Medicine Research, Coast, Kilifi District Hospital, Kilifi, Kenya [8]Bandim Health Project, Apartado 861, Bissau, Guinea-Bissau [9]Service de Pneumo-Phtisiologie, University Ignace Deen, Conakry, BP 634, Republic of Guinea [10]MRC Laboratories, Fajara, The Gambia [11]Center for Tropical Diseases, Cho Quan Hospital, Ho Chi Minh City, Vietnam [12]Service de la Tuberculose, Institut Pasteur d'Algérie. 2, Rue du Dr Laveran Hamma, Algiers, Algeria

Abstract

Toll-like receptors (TLRs) and members of their signalling pathway play an important role in the initiation of the innate immune response to a wide variety of pathogens1,2,3. The adaptor protein TIRAP mediates downstream signalling of TLR-2 and -44,5,6. We report a case-control genetic association study of 6106 individuals from Gambia, Kenya, United Kingdom, and Vietnam, with invasive pneumococcal disease, bacteraemia, malaria and tuberculosis. Thirty-three SNPs were genotyped, including *TIRAP* S180L. Heterozygous carriage of this variant was found to associate independently with all four infectious diseases in the different study populations (*P*=0.003, OR=0.59, 95%CI 0.42-0.83 for IPD; *P*=0.003, OR=0.40, 95%CI 0.21-0.77 for bacteraemia; *P*=0.002, OR=0.47, 95%CI 0.28-0.76 for malaria; *P*=0.008, OR=0.23 95%CI 0.07-0.73 for tuberculosis). Substantial support for a protective effect of S180L heterozygosity against infectious diseases was observed when the study groups were combined (N=6106, Overall

P 9.6×10^{-8}). Tirap S180L was also shown to be functionally impaired in TLR2 signal transduction.

Toll-like receptors (TLRs) recognise a diverse array of pathogens and initiate intracellular signalling via their Toll/Interleukin-1 receptor (TIR)-domains, leading to differential effects on gene expression and the generation of an inflammatory host response. TLR2 has been shown to recognise, among other agonists, lipoteichoic acid, lipoarabinomannan and mycobacterial lipopeptides[1], whilst TLR4 recognises lipopolysaccharide (LPS)[7,8,9]. Both TLRs 2 and 4 sense *P. falciparum* glycosylphosphatidylinositol (GPI) (Aucan *et al.* unpublished data)[10]. The adaptor protein TIRAP (TIR domain-containing adaptor protein), also known as MAL (MYD88 adapter-like), is essential for MYD88-dependent signalling downstream of TLR2 (with TLR1 and TLR6 as co-receptors) and TLR4[1,5]. Following stimulation of TLR2 or TLR4, TIRAP triggers a signalling cascade which culminates in the activation of the transcription factor NF-κB and the subsequent activation of pro-inflammatory genes. Based on the central position of TIRAP in the TLR2 and TLR4 pathways, and knowledge of the microbial components which associate with these TLRs, we hypothesised that genetic variation at *TIRAP* might underlie susceptibility to common infectious diseases.

TIRAP spans 14500 base pairs on Chr11q24.2 and encodes a protein of 221 amino acids. Analyzing thirty-three SNPs in *TIRAP* and surrounding region in multiple populations found *TIRAP* S180L consistently associated with disease (Supplementary Note, Fig. 1, Table 1 and 2 online). *TIRAP* S180L genotyping was performed in a total of 6106 individuals with four different diseases: two United Kingdom (UK) populations of European ancestry with invasive pneumococcal disease (IPD); a Kenyan population with bacteraemia; three populations with malaria, (from The Gambia, Kenya, and Vietnam); and two populations with tuberculosis (from Algeria as well as the West African populations of The Gambia, Guinea-Bissau and the Republic of Guinea).

In the UK population, heterozygosity at *TIRAP* S180L was associated with protection from invasive pneumococcal disease (3×2 χ^2=8.72, P=0.013, Table 1). An excess of mutant homozygotes amongst IPD cases (Table 1) was also observed in this UK population. *TIRAP* S180L was then examined in a separate group of UK individuals with thoracic empyema and a second control group. Although no association was observed between genotype and susceptibility to thoracic empyema overall (n=584, 3×2 χ^2=0.63, P=0.73), analysis of the small subgroup of individuals with pneumococcal empyema revealed a non-significant trend towards association (3×2 χ^2=5.05, P=0.080; Table 1). Interestingly, an excess of mutant homozygotes was again observed amongst this second group of IPD cases (Table 1).

We then studied *TIRAP* S180L in a second population with invasive bacterial disease, comprising Kenyan children with well-defined bacteraemia. Although the mutant allele was found to be less common in the Kenyan population than in UK individuals, the same pattern of association was observed. The *TIRAP* S180L heterozygotes were significantly more common amongst community controls (5.9%), compared to individuals with bacteraemia (2.4%) (2×2 χ^2=9.05, P=0.003; Table 1). The heterozygote protective effect of the S180L locus was also significant within the subgroup of 164 Kenyan children with pneumococcal bacteraemia (F_{exact}=0.024, Table 1), thus replicating the findings in the UK studies.

In the Gambian malaria case-control study, *TIRAP* S180L heterozygosity demonstrated a significant protective effect against both general malaria (Wald=8.35, P=0.004, Table 1) and severe malaria (Wald=8.706, P=0.003, Table 1). This result was replicated in a second malaria case-control study, this time in a Vietnamese population whose design included only cases of severe malaria: *TIRAP* S180L heterozygotes were again found to be more prevalent

among the controls (4.7%) compared to the severe malaria cases (1.1%) (F_{exact}=0.046, Table 1). An attempt to replicate this in a third malaria case-control study (from Kenya) demonstrated similar results (2×2 χ^2 =3.28, P=0.035; Table 1).

Finally, the possible effect of the *TIRAP* S180L polymorphism on susceptibility to tuberculosis was examined in 1280 individuals from The Gambia, Guinea-Bissau and the Republic of Guinea (collectively known as the EUTB West African study), again with ethnically matched controls. The *TIRAP* S180L heterozygous genotype was found to be protective against clinical tuberculosis (*Wald*=6.23, *P*=0.013). This finding was then replicated in two family-based studies on tuberculosis: from the EUTB West African study, as well as from Algeria. In both studies, the variant *TIRAP* S180L was found to be under-transmitted in subjects with clinical tuberculosis compared to subjects free from clinical tuberculosis (TRANSMIT *P*=0.075 and *P*=0.038 respectively; Table 2).

When all the study groups are combined and stratified for the different populations, there is a clear association between heterozygosity at the *TIRAP* S180L locus and protection against multiple infectious diseases (N=6106, *P* 9.6×10^{-8}). To our knowledge, there are no other samples where we (or others) have tried and failed to replicate this finding. Studies on the functional effect of the S180L variant were consequently undertaken.

We first assayed the effect of the S180L polymorphism on TLR2 signalling using transfected murine embryonic fibroblasts (MEFs) from *Tirap* knockout mice (Fig. 1). Treatment of wild type MEFs with the TLR2 ligand Malp2 induced I-κBα degradation at 30 and 50 minutes (first panel). This effect was absent in *Tirap*-deficient MEFs (second panel). However, transfection of *Tirap* knock-out cells with the wild-type 180-Ser fully reconstituted TLR2 signalling, with degradation of IκB-α occurring at 30 and 50 minutes post-treatment (third panel). Transfection with the mutant 180-Leu failed to result in IκB-α degradation following TLR2 stimulation (fourth panel). Both wild-type 180-Ser and variant 180-Leu were expressed at similar levels in the cells (not shown).

A similar lack of reconstitution was observed when IL-6 was measured, as shown in Fig. 2. Both LPS and Malp2 induced IL-6 in wild-type MEFs causing a 4-fold increase over untreated cells (first histobar in each set). The effect of both stimuli was however abolished in *Tirap*-deficient cells (second histobar in each set). Transfection of the *Tirap*-deficient cells with a plasmid encoding wild-type Tirap 180-Ser reconstituted the effect of both LPS and Malp2, leading to a 3-fold stimulation over untreated cells (third histobar in each set). The variant Tirap 180-Leu was however unable to reconstitute the effect of either stimulus (fourth histobar in each set). Both wild-type 180-Ser and variant 180-Leu were expressed at similar levels in the cells (lower panel). We also tested the functional consequences of co-expression of wild-type 180-Ser and variant 180-Leu in Tirap-deficient cells. As shown in Fig. 3, expression of wild-type 180-Ser Tirap activated an NF-κB-linked reporter gene (second histobar). The variant 180-Leu form was however inactive in cells lacking endogenous Tirap (third histobar), attesting further to the functional deficiency of this form of Tirap. Importantly, the variant form inhibited the ability of the wild-type form of Tirap to activate NF-κB (fourth histobar). This suggests that TIRAP signalling will be directly impaired in heterozygotes, since the variant might interfere with signalling by the wild-type form.

Wild-type TIRAP has been shown previously to interact with TLR2[11]. We generated models of the wild-type and mutant protein in order to assess the effect of the S180L mutation on TIRAP structure. According to our model (Fig. 4), serine 180 is located on the edge of a surface-exposed loop opposite the BB-loop, the region that contains a critical proline residue that has been shown for other TIR containing proteins to form a point of

contact with downstream signalling molecules. The model predicts that the electrostatic surface potential does not differ significantly between the wild-type and mutant protein. However the leucine residue appears to be more exposed (Fig. 4 upper panel). Previous modelling and interaction studies have suggested that TIRAP may bind to TLR2 via a region termed the DD-loop[11]. In our current model, Serine 180 is located in close proximity to this DD-loop (Fig. 4 lower panel). We therefore performed an *in vitro* binding assay in order to assess the effect of the mutation on the TIRAP: TLR2 interaction. As shown in Fig. 5 upper panel, a GST-tagged version of the TIRAP 180-Leu containing allotype, unlike wild-type TIRAP, failed to bind to TLR2 suggesting that the defect in reconstitution of signalling by TIRAP S180L occurs as a result of TLR2 not recruiting the variant. In addition to TLR2, TIRAP has also been shown to bind to both itself and MyD88[4]. We therefore tested the effect of the S180L mutation on these interactions. As shown in Fig. 5, middle and lower panel, respectively, the S180L mutation had no effect on the interaction of TIRAP with both itself and MyD88.

Studies in Tirap-deficient mice have demonstrated impaired cytokine responses and NF-κB activation following stimulation with ligands at TLR4 and TLR2, as well as the TLR2 co-receptors TLR1 and TLR6[5,6]. Unlike bacterial components[1,12,13], the interaction of malaria parasites with TLRs is less well-described, although it has been demonstrated that *P. falciparum*-derived GPI is a ligand for both TLR2 and TLR4[10] (Aucan *et al.* unpublished data). The association between *TIRAP* variants and malaria in Gambian and Vietnamese populations presented here provides further evidence for a role of the TLR pathway in malaria pathogenesis. In addition, a role for the TLR2 system in host defence against malaria is also suggested from mutations in CD36, which associate with susceptibility to severe malaria[14]. Recently, CD36 has been shown to be a co-receptor for TLR2[15]. Taken with the *TIRAP* variant presented here, the TLR2 system is clearly important for the host response in malaria.

On the basis of our co-transfection experiments (Fig. 3), the protective heterozygote state is likely to be associated with attenuated signaling and reduced NF-κB activation. This finding is consistent with increasing evidence that an excessive host inflammatory response may render individuals more vulnerable to developing severe forms of malaria and bacterial disease[16,17,18]. On the other hand, too little signaling would lead to an inadequate anti-pathogen response. This provides the opportunity for intermediate genotypes regulating signaling to be of optimal protective value. The mutant homozygotes are too rare to assess in African and Vietnamese populations, although in each of the UK studies there is a significant association with increased susceptibility to IPD amongst mutant homozygotes. This may have occurred by chance through analysis of the relatively small number of mutant homozygote individuals, or alternatively it may reflect a true heterozygote protective effect. Heterozygote protection against infectious disease is well recognized with examples such as sickle cell trait and malaria, prion protein gene variation and spongiform encephalopathy, and HLA and HIV/AIDS disease progression[19,20,21]. If the *TIRAP* 180-Leu homozygous state does indeed confer increased susceptibility to IPD, the mechanism by which this occurs is unclear, although we speculate that it may result in severely impaired or abolished signaling and increased susceptibility to severe infection, as has also been demonstrated in patients with rare functional mutations in *IRAK4* and *NEMO* in the same pathway[22,23]. We suggest that heterozygosity at S180L may therefore confer a protective phenotype characterized by intermediate levels of pathway activation and an 'optimal', balanced inflammatory response. Additional host and microbial factors such as pathogen virulence and dose and prior immunity might be expected to interact with this model, as described in murine models of pneumococcal susceptibility[24], and the optimal level of inflammatory response to a given exposure will likely vary depending on such factors.

The rarity of the mutant allele in African populations is also noteworthy. The burden of infectious disease mortality is very high in African populations, and this may strongly select against mutant homozygote individuals and act to reduce the 180-Leu allele frequency. The observed allele frequency may reflect a balance between protection afforded to heterozygotes and increased susceptibility to infectious disease in mutant homozygotes. It is also possible that the Leu allele may be subject to ongoing selective pressure and has not yet achieved fixation in the African population. Furthermore, it is conceivable that *TIRAP* S180L may influence susceptibility to other common infectious and inflammatory causes of death and so be subject to multiple selective pressures which may differ between human populations and ecological settings. Investigation of the role of this functional variant of TIRAP in susceptibility to other diseases may shed light on this area. We report here the first single nucleotide change that appears to impact on numerous major infectious diseases, roughly halving the risk in heterozygous individuals. This should represent a major evolutionary pressure as these diseases together account for over five million deaths each year in the developing world.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Appendix

METHODS

Sample collections

The UK IPD, thoracic empyema, Gambian malaria, West African tuberculosis and Kenyan bacteraemia study groups have previously been described in detail. Informed consent and written approval from the relevant ethical review boards has been granted for all sample collections. Overviews of the sample collections are presented in the online Supplementary Methods.

Sample genotyping

Direct sequencing of the *TIRAP* coding exons, a 1500 base pair region immediately 5′ to the transcription start site, and the 3′ untranslated region was performed in 48 Gambian individuals. The databases searched include dbSNP and Ensembl (www.ensembl.org). The *TIRAP* S180L polymorphism was genotyped using the Sequenom Mass-Array® MALDI-TOF primer extension assay for the Gambian malaria, Kenyan bacteraemia and UK IPD study groups25. Confirmation via direct sequencing with BigDye v3.1 terminator mix (ABI) was then performed on 12 randomly selected wild type and 12 heterozygous mutant samples from each of these populations. For the Vietnamese sample set, genotyping was performed using a site-directed mutagenesis assisted restriction fragment length polymorphism (RFLP)

assay, and for the Gambian tuberculosis study group, genotyping was performed using the RFLP assay and confirmed by both the Sequenom Mass-Array® MALDI-TOF primer extension assay and direct sequencing. The rarity of the S180L polymorphism in the African populations studied increases the risk of bias due to genotyping error. To address this issue, all genotypes containing the mutant allele in these populations were confirmed by direct sequencing. The -80708, -68168, -52070, -29144, -23852, -18304, -12534, -5289, -4570, -1580, -386, -355, +177, +3977, +6032, +7685, R13W, S55N, Q101Q, S180L, A186A, V197I, +10122, +10610, +11347, +13466, +13955, +14472, +21162, +35464, +44402, +60339 and +71446 polymorphisms were genotyped via the Sequenom Mass-Array® assay. Details of the genotyping methodology for all markers genotyped above are available in the Supplementary Note and Methods, as well as appended in Supplementary Table 1 and 2 online. The individual assay details can be found in Supplementary Table 3 online. All control genotype frequencies were in Hardy-Weinberg equilibrium.

Statistical methods

Statistical analysis of genotype frequencies was performed with Chi-squared tests, two tailed Fisher's exact tests if the Chi-squared test was inappropriate and forward, stepwise logistic regression, using the program SPSS. $P<0.05$ was considered significant. One tailed P values were computed if statistical testing was performed on a sample set replicating the same disease state. The overall, two-tailed P value for the combined analysis was computed using the method similar to that previously described[26]. Analysis of linkage disequilibrium was performed using the HaploView v3.2 program[27]. Analysis of transmission disequilibrium was performed using the program TRANSMIT[28].

Functional analysis

Reporter Gene Assays—Tirap-deficient MEFs (2×10^4 cells/well) were seeded into 96-well plates, transfected as described[4] on the following day with pcDNA3-Mal-HA or pcDNA3-MalS180L-HA as indicated (which was generated using the Quikchange™ kit (Stratagene)), in combination with luciferase reporter gene (80 ng well-1 κB-luciferase) and with *Renilla*-luciferase reporter gene (40 ng) as an internal control. Cell lysates were prepared as previously described[4].

Reconstitution Assays—Murine embryonic fibroblasts (MEFs) were transfected with plasmids encoding Tirap, Tirap-S180L or empty vector using metafectene essentially as described by the manufacturers (Biontex). After 48 hrs, cells were treated with LPS (1μg/ml) or Malp2 (5 nM) for the indicated times. Immunoblot analysis was performed using a monoclonal anti-IκBα antibody, phosphor-p38 antibody or anti-β-actin as loading control (all from Santa Cruz, CA, USA) as indicated. IL-6 levels were measured by ELISA according to the manufacturer's recommendation (R and D Systems).

GST-Pulldown Assays—The pGEX-Mal construct has been described previously[11]. The S180L point mutation was generated using the QuickChange® site-directed mutagenesis kit (Stratagene) according the protocol of the manufacturer. HEK293 cells were seeded (10^5 ml^{-1}) onto 100 mm dishes 24 hours prior to transfection with 3 μg of Flag-tagged TLR2, HA-tagged Tirap or AU1-tagged MyD88 using Genejuice (Novagen) according to the manufacturer's recommendations. 24 hours post-transfection cells were washed by the addition of 3 ml of ice-cold phosphate buffered saline (PBS). Cells were lysed at 4°C (1 hr) in buffer containing 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1% NP-40, 0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM Na_3VO_4 and 1μg of leupeptin ml^{-1}. GST-pulldown assays were performed using the recombinant wild-type and mutant GST-Tirap proteins coupled to GSH-sepharose. Lysis extracts were incubated for 2 hours with the fusions indicated in the figure legends. The complexes were washed 3 times in lysis buffer and

subjected to SDS-PAGE and western blotting. Monoclonal antibodies against the FLAG (12CA5) and AU-1 epitopes were obtained from Sigma and Berkeley Antibody Company (BAbCo), respectively. The polyclonal antibody against the HA-epitope tag (Y-11) was obtained from Santa Cruz Biotechnology.

References

1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunology. 2004; 4:499–511. [PubMed: 15229469]

2. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21:335–76. [PubMed: 12524386]

3. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2:675–80. [PubMed: 11477402]

4. Fitzgerald KA, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature. Sep 6; 2001 413(6851):78–83. [PubMed: 11544529]

5. Yamamoto M, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature. 2002; 420:324–329. [PubMed: 12447441]

6. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 2002; 420:329–333. [PubMed: 12447442]

7. Poltorak A, et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998; 282:2085–8. [PubMed: 9851930]

8. Hoshino K, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999; 162:3749–52. [PubMed: 10201887]

9. Shimazu R, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999; 189:1777–82. [PubMed: 10359581]

10. Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, Akira S, Woods AS, Gowda DC. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signalling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem. Mar 4; 2005 280(9):8606–16. [PubMed: 15623512]

11. Dunne A, Ejdeback M, Ludidi PL, O'Neill LA, Gay NJ. Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors TIRAP and MyD88. J.Biol.Chem. 2003; 278(42):41443–51. [PubMed: 12888566]

12. Thoma-Uszynski S, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science. 2001; 291:1544–1547. [PubMed: 11222859]

13. Malley R, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. PNAS. 2003; 100(4):1966–1971. [PubMed: 12569171]

14. Aitman TJ, et al. Malaria susceptibility and CD36 mutation. Nature. Jun 29; 2000 405(6790): 1015–6. [PubMed: 10890433]

15. Hoebe K, et al. CD36 is a sensor of diacylglycerides. Nature. Feb 3; 2005 433(7025):523–7. [PubMed: 15690042]

16. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002; 415:673–679. [PubMed: 11832955]

17. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005; 365(9453):63–78. [PubMed: 15639681]

18. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995; 377:435–438. [PubMed: 7566121]

19. Dean M, Carrington M, O'Brien SJ. Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet. 2002; 3:263–92. [PubMed: 12142357]

20. Mead S, Stumpf MP, Whitfield J, Beck JA, Poulter M, Campbell T, Uphill JB, Goldstein D, Alpers M, Fisher EM, Collinge J. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science. 2003; 300:640–3. [PubMed: 12690204]

21. Carrington M, Nelson GW, Martin MP, Kissner T, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999; 283:1748–52. [PubMed: 10073943]

22. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003; 299:2076–2079. [PubMed: 12637671]

23. Doffinger R, Smahi A, Bessia C, Geissmann F, Feinberg J, Durandy A, Bodemer C, Kenwrick S, Dupuis-Girod S, Blanche S, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet. 2001; 27:277–285. [PubMed: 11242109]

24. Clatworthy MR, Smith KG. FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J Exp Med. 2004; 199:717–23. [PubMed: 14981111]

25. Jurinke C, van den Boom D, Cantor CR, Koster H. The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol. 2002; 77:57–74. [PubMed: 12227737]

26. Altshuler D, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. Sep 26.2000 (1):76–80. [PubMed: 10973253]

27. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21(2):263–265. [PubMed: 15297300]

28. Clayton D. Am J Hum Genet. 1999; 65:1170. [PubMed: 10486336]

Wild type MEFs

Tirap-deficient MEFs

Tirap-deficient MEFs reconstituted with wild type Tirap

Tirap-deficient MEFs reconstituted with Tirap S180L

Figure 1.
Macrophage-activating lipopeptide 2 (Malp2) induced, TLR2 signalling assay as measured by degradation of IκB-α at various time points. First panel: Malp2 (5nM) -stimulated wild-type murine embryonic fibroblast (MEF) cells. Second panel: Malp2-stimulated *Tirap* knockout cells. Third panel: Malp2-stimulated *Tirap* knockout cells transfected with *Tirap* 180-Ser. Fourth panel: Malp2-stimulated *Tirap* knockout cells transfected with *Tirap* 180-Leu. Samples were immunoblotted with an anti-I IκB-α antibody. Protein loading was controlled for using the β-actin housekeeping gene. Results shown are representative of 3 separate experiments.

■ *Tirap* WT + EV

□ *Tirap* KO + EV

▨ *Tirap* KO + *Tirap* WT

▨ *Tirap* KO + *Tirap*-S180L

Fold stimulation IL6 production

LPS   Malp-2

Tirap S180 (wild-type)   **Tirap L180 (variant)**

0   LPS   MALP-2   0   LPS   MALP-2

Figure 2.
Wild-type MEFs or *Tirap* knockout MEFs transfected with empty vector or plasmids encoding Tirap 180-Ser or Tirap 180-Leu as indicated, were treated with LPS (1µg/ml) or Malp2 (5nM). After 24h, supernatants were removed and assayed for IL-6 by ELISA. Expression levels of Tirap S180 and Tirap L180 in the cells analysed (untreated or treated with LPS or Malp2 for 24h) are shown in the lower panel. Results shown are mean ± s.e.m. of triplicate determinations, similar results being obtained in 2 further experiments.

Tirap KO MEFS

Figure 3.
Tirap knockout MEFs were transfected with 100ng empty vector, or plasmids encoding Tirap 180-Ser or Tirap 180-Leu (50ng of each, supplemented to 100ng with 50ng of empty vector), or a combination of plasmids encoding Tirap 180-Ser and Tirap 180-Leu (50ng of each) as indicated, each in combination with luciferase reporter gene (80 ng per well 5 x NF-κB-luciferase) with *Renilla*-luciferase reporter gene (40 ng) as an internal control. Cell lysates were prepared as previously described4. Results shown are mean + S.D. from triplicate determinations.

Figure 4.
Molecular models of wild-type and mutant TIRAP. The computational utility Molecular Operating Environment (MOE2006.02) (www.chemcomp.com) was used to generate the models. Electrostatic surface potentials are highlighted in blue (positive) and red (negative) (upper panel). Structural features are highlighted in the lower panel. Box 1, the TIRAP BB loop and the position of Serine 180 are all indicated.

Figure 5.
HEK-293 cells (1×10^6) were transfected with 3 μg of Flag-tagged TLR2, HA-Tirap or AU1-tagged MyD88. Lysates were incubated with purified glutathione-coupled GST, GST-Tirap and GST-Tirap S180L for 2 hrs. After washing, the complex was analysed by SDS-PAGE and western blotting. Results shown are representative of 3 separate experiments.

Table 1

TIRAP S180L genotype frequencies in individuals with infectious disease and controls

Population	Status	Genotype distribution. No. individuals (%)			P value[a] [adjusted P value[b]]	Heterozygote advantage model OR (95%c.i.)
		Ser/Ser	Ser/Leu	Leu/Leu		
UK	Control (1)	527 (71.1%)	199 (26.9%)	15 (2.0%)	**0.013**[h] **[0.031]**	0.65 (0.44-0.97)[c,d]
	IPD	146 (76.4%)	36 (18.8%)	9 (4.7%)		
	Control (2)	246 (68.1%)	107 (29.6%)	8 (2.2%)	0.080[i] [0.080]	0.74 (0.32-1.68)[e]
	Pneumococcal empyema	25 (69.4%)	8 (22.2%)	3 (8.3%)		
Kenyan	Control	398 (94.1%)	25 (5.9%)	0 (0%)	**0.003**[j] **[0.003]**	0.34 (0.17-0.69)
	Overall bacteraemia[+]	719 (97.6%)	18 (2.4%)	0 (0%)		
	Pneumococcal bacteraemia[g]	161 (98.2%)	3 (1.8%)	0 (0%)	**0.024**[//] **[0.056]**	0.30 (0.06-0.99)
Gambian	Control	172 (96.6%)	6 (3.4%)	0 (0%)	**0.025**[f] **[0.004]**	0.15 (0.043-0.55)
	General malaria	652 (99.1%)	6 (0.9%)	0 (0%)		
	Severe malaria	413 (99.3%)	3 (0.7%)	0 (0%)	**0.024**[f] **[0.003]**	0.04 (0.004-0.34)
Vietnamese	Control	81 (95.3%)	4 (4.7%)	0 (0%)	**0.046**[//] **[0.041]**	0.23 (0.056-0.94)
	Severe malaria	357 (98.9%)	4 (1.1%)	0 (0%)		
Kenyan	Control	398 (94.1%)	25 (5.9%)	0 (0%)	0.035[k //] [0.035]	0.58 (0.31-1.09)
	Severe malaria	599 (96.5%)	22 (3.5%)	0 (0%)		
West African(The Gambia, Guinea-Bissau, Republic of Guinea)	Control	593 (98.0%)	12 (2.0%)	0 (0%)	**0.041**[f] **[0.013]**	0.23 (0.07-0.73)
	Tuberculosis	671 (99.4%)	4 (0.6%)	0 (0%)		

[a] 2×2 or 3×2 Chi-squared comparisons of genotypes, depending on the presence or absence of mutant homozygotes in the different populations.

[b] Following logistic regression for confounding factors in the different diseases (sickle cell trait, age, ethnicity, age, and homestead for malaria; HIV status, malnutrition, and age for bacteraemia; HIV status, ethnicity, age, and sex for tuberculosis; comorbid conditions and age for IPD). The Hosmer-Lemeshow goodness of fit tests was not significant ($P>0.05$) for any of the logistic regression models, indicating that the phenotypes predicted by the logistic regression models fitted with the observed phenotypes.

[c] Logistic regression using the wild-type Ser/Ser homozygotes as reference.

[d] Odds ratio of the Leu/Leu homozygotes = 2.39, 95%CI: 0.95-5.92.

[e] Odds ratio of the Leu/Leu homozygotes = 4.01, 95%CI: 0.65-17.66.

[f] Two-tailed Fisher's exact test.

[g]The Kenyan pneumococcal bacteraemia cases are a subset of the Kenyan bacteraemia case population, and the result here is analysed against the same Kenyan controls. The data relating to pneumococcal cases was not included separately in the combined analysis; only the overall Kenyan bacteraemia case-control data was included.

[h]3×2 Chi-square=8.72.

[i]3×2 Chi-square=5.05.

[j]2×2 Chi-square=9.05.

[k]2×2 Chi-square=3.28

[ll]One tailed P values were used for replication sets.

[+]Protection afforded by the heterozygote variant was seen for individuals suffering from both Gram-positive bacteraemia (2×2 χ^2 =5.18, P=0.023, OR=0.40, 95%CI: 0.16–0.95) and Gram-negative bacteraemia (2×2 χ^2 =6.82, P=0.009, OR=0.38, 95%CI: 0.17–0.85). Correction for the effects of HIV status, malnutrition, and age using binary logistic regression did not affect the observed associations.

Table 2

Transmission Disequilibrium Test (TDT) results of *TIRAP* S180L in West Africa and Algeria

Algeria				
	All sibs		One sib	
Genotype	Observed	Expected	Observed	Expected
180-SS	159	150.92	74	70.346
180-SL	15	23.079	10	13.654
P [//]	**0.020**		**0.038**	
West Africa				
	All sibs		One sib	
Genotype	Observed	Expected	Observed	Expected
180-SS	259	258.23	259	258.23
180-SL	1	1.779	1	1.779
P [//]	**0.075**		**0.075**	
Combined Algerian and West African family study: $P^{//}$=0.016				
Combined data from all studies: P 9.6×10^{-8}.				

[//]One tailed *P* values were used.